Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs SNOA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SNOA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–2 Matrix Metrics)
SNOA Overall Winner
6-Pillar Tally: BMRA 0 – 5 SNOA (1 Tie)
Matrix Metrics: BMRA 2 – 7 SNOA
As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas SNOA carries 51.6/100 (HOLD) at $0.95 (46.1x Forward P/E, -3.3% operating margin).
- Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile SNOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BMRA vs SNOA
BMRA
Biomerica Inc
$1.36
+0.0% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
SNOA
Head-to-Head Winner
Sonoma Pharmaceuticals, Inc. Common Stock
$0.95
-12.84% 1D
Market Cap
$5.6M
TTM Revenue
$23M
Forward P/E
46.1x
Beta / 30D Vol
1.27β · 66% Vol
Unified Composite Score
51.6
HOLD
Tech 49.0
Fund 52.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 5 SNOA)
1. Valuation Multiples
SNOA
Forward P/E
N/M
46.1x
Trailing P/E
N/M
46.1x
PEG Ratio
N/M
1.08x
EV / Revenue
1.1x
0.2x
2. Growth & Scale
SNOA
Revenue Growth (YoY)
-8.3%
+28.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.3M
$23M
Market Cap
$6.0M
$5.6M
3. Profitability & Quality
SNOA
Gross Margin
0.9%
39.2%
Operating Margin
-125.2%
-3.3%
Net Profit Margin
-115.5%
-7.6%
Return on Equity (ROE)
-113.8%
-34.5%
4. Balance Sheet & Cash Flow
SNOA
Cash Generation (TTM)
-$3.2M
-$4.1M
Cash Flow Margin
-73.5%
-17.6%
Net Cash / Leverage
$1.1M Net Cash
$1.6M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
SNOA
OpEx & R&D Intensity
N/A
42.5% of Rev ($10.0M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BMRA (2) vs SNOA (7)| Institutional Metric | BMRA | SNOA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.0M | $5.6M | Tie | |
| Trailing P/E Ratio | N/M | 46.1x | SNOA | |
| Forward P/E Ratio | N/M | 46.1x | SNOA | |
| Revenue Growth (YoY) | -8.3% | +28.0% | SNOA | |
| Operating Margin (TTM) | -125.2% | -3.3% | SNOA | |
| Net Profit Margin | -115.5% | -7.6% | SNOA | |
| Return on Equity (ROE) | -113.8% | -34.5% | SNOA | |
| 52-Week Range Position | 5% ($1–$3) | 3% ($1–$4) | BMRA | |
| Beta / 30D Volatility | 0.67β · 62% Vol | 1.27β · 66% Vol | BMRA | |
| Unified Institutional Score | 44.5 / 100 (HOLD) | 51.6 / 100 (HOLD) | SNOA | |
| Trailing 12M Revenue (USD) | $4.3M | $23M | Scale | |
| Gross Profit Margin (TTM) | 0.9% | 39.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.1x EV/Rev | 1.08x PEG · 0.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$3.2M ($1.1M Net Cash) | -$4.1M ($1.6M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SNOA +11.31 pp
3M Horizon
BMRA +11.92 pp
6M Horizon
SNOA +31.79 pp
1Y Horizon
BMRA +27.56 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | SNOA Revenue | BMRA Op. Margin | SNOA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $20M | -46.4% | -59.3% | BMRA |
| FY2020 | $10M | $20M | -41.0% | -41.2% | BMRA |
| FY2021 | $10M | $20M | -104.2% | -18.5% | SNOA |
| FY2022 | $20M | $10M | -24.0% | -46.6% | BMRA |
| FY2023 | $10M | $10M | -135.3% | -34.4% | SNOA |
| FY2024 | $10M | $10M | -117.6% | -36.9% | SNOA |
| FY2025 | $10M | $10M | -96.7% | -26.0% | SNOA |
| FY2026 | $0M | $20M | -119.5% | -12.6% | SNOA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SNOA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SNOA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SNOA Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
42.5% of Rev ($10.0M)
90D Engineering Disclosures
0 Published
Investor FAQ BMRA vs SNOA Key Questions & Quantitative Answers
As of Nov 16, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas SNOA carries 51.6/100 (HOLD) at $0.95 (46.1x Forward P/E, -3.3% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile SNOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SNOA leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with SNOA at +28.0% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (39.2% gross margin, -3.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while SNOA shifted +0.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 42.5% of Rev ($10.0M) (0 disclosures) for SNOA.
SNOA screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas SNOA trades at 46.1x Forward P/E, 46.1x Trailing P/E, 1.08x PEG, and 0.2x EV/Revenue (-17.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus SNOA (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, SNOA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.27β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SNOA vs BMRA · Reverse Pair
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal